|
Form Serial Number: |
CS20180926E00306 |
1.
Date of relevant event: |
20/09/2018 (dd/mm/yyyy)
|
2.
Date when the substantial shareholder becomes aware of the relevant event / interest in the shares (if later): |
(dd/mm/yyyy)
|
3.
Stock code: |
01548 |
4.
Name of listed corporation: |
Genscript Biotech Corporation |
5.
Class of shares: |
Ordinary Shares |
6.
Number of issued shares in class: |
1,833,270,111 |
7.
Name of substantial shareholder: |
Genscript Corporation |
8.
Registered office: |
Suite 606, 1220 N. Market Street, Wilmington, DE 19801, County of New Castle, USA |
9.
Principal place of business in Hong Kong: |
N/A |
15.
Exchange on which listed: |
|
16.
Name of listed parent and exchange on which parent is listed: |
|
|
17.
Details of relevant event: |
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved |
Currency of transaction |
On Exchange
|
Off Exchange
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Nature of consideration
|
Long position |
1710 | Miscellaneous Voluntary disclosure (you must briefly describe the relevant event in the Supplementary Information box) |
|
|
|
|
|
|
|
|
|
Short position |
|
|
|
|
|
|
|
|
|
|
|
18.
Total shares immediately before the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 887,402,024 | 48.36 |
|
|
19.
Total shares immediately after the relevant event: |
| Total number of shares | Percentage figure (%) |
Long position | 887,402,024 | 48.40 |
|
|
20.
Capacity in which interests disclosed in Box 19 are held: |
Capacity code | Number of shares |
| |
|
|
|
21.
Further information in respect of derivative interests: |
Derivatives code | Number of shares |
| |
|
|
22.
Further information in relation to interests of corporations controlled by substantial shareholder: |
Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
|
23.
Further information in relation to interests held by substantial shareholder jointly with another person: |
Name of joint shareholder | Address | Number of shares |
| | |
|
|
24.
Further information from a trustee, a beneficiary of a trust, or a person who set up a discretionary trust: |
Names of trust | Address | Status code | Number of shares |
| | | |
|
|
25.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
Names of other parties | Address | Number of shares |
| | |
Total number of shares in which a substantial shareholder is interested under sections 317 and 318 | |
|
|
26.
Details of person(s) in accordance with whose directions the substantial shareholder or its directors are accustomed to act: |
Names | Address | Relationship Code | Percentage (%) |
Zhang Fangliang | Addresses of individuals are not displayed. | 6104 | Controller is a director |
| 28.82 |
|
|
27.
Supplementary information: |
A total of 1,660,000 shares of Genscript Biotech Corporation (the "Company") repurchased on 13 September 2018 and 14 September 2018 (as disclosed in the voluntary announcements of the Company dated 13 September 2018 and 14 September 2018) were canceled on 20 September 2018.
|
28.
Log/Serial Number of the previous form: |
|
29.
Number of concert party document(s) under section 317 attached/uploaded: |
|
Date of filing this Form 2: |
26/09/2018 (dd/mm/yyyy)
|
|
|
|
|